Effect of Varenicline on Tardive Dyskinesia: A Pilot Study
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: Although evidence implicates striatal cholinergic impairment as a mechanism underlying tardive dyskinesia, trials of nonspecific cholinergic agents have been inconclusive. As a partial agonist at specific nicotinic receptor subtypes, varenicline reduces drug-induced dyskinesias in animal models suggesting promise as a treatment for tardive dyskinesia. Methods: Three schizophrenia patients with tardive dyskinesia who were smokers underwent an open trial of varenicline. After a 2-week baseline, subjects received varenicline 1 mg twice daily. Changes from baseline on the Abnormal Involuntary Movement Scale were measured after a 4-week varenicline stabilization period, and 6 weeks after the smoking quit date in one patient. Results: Varenicline had no effect on mean Abnormal Involuntary Movement Scale scores after 4 weeks. Although smoking decreased after 4 weeks on varenicline and diminished further in one patient after 10 weeks, this also appeared to have no effect on ratings of tardive dyskinesia. Conclusion: In contrast to animal models, no significant change in tardive dyskinesia occurred in response to varenicline replacement in three schizophrenia patients. Further investigations of cholinergic mechanisms in tardive dyskinesia are worthwhile as agents for specific cholinergic targets become available for treatment. In addition, treatment trials of tardive dyskinesia should control for smoking status, while patients on antipsychotics receiving nicotine replacement therapies for smoking should be studied further for changes in movement.
Abstract
Objective: Although evidence implicates striatal cholinergic impairment as a mechanism underlying tardive dyskinesia, trials of nonspecific cholinergic agents have been inconclusive. As a partial agonist at specific nicotinic receptor subtypes, varenicline reduces drug-induced dyskinesias in animal models suggesting promise as a treatment for tardive dyskinesia. Methods: Three schizophrenia patients with tardive dyskinesia who were smokers underwent an open trial of varenicline. After a 2-week baseline, subjects received varenicline 1 mg twice daily. Changes from baseline on the Abnormal Involuntary Movement Scale were measured after a 4-week varenicline stabilization period, and 6 weeks after the smoking quit date in one patient. Results: Varenicline had no effect on mean Abnormal Involuntary Movement Scale scores after 4 weeks. Although smoking decreased after 4 weeks on varenicline and diminished further in one patient after 10 weeks, this also appeared to have no effect on ratings of tardive dyskinesia. Conclusion: In contrast to animal models, no significant change in tardive dyskinesia occurred in response to varenicline replacement in three schizophrenia patients. Further investigations of cholinergic mechanisms in tardive dyskinesia are worthwhile as agents for specific cholinergic targets become available for treatment. In addition, treatment trials of tardive dyskinesia should control for smoking status, while patients on antipsychotics receiving nicotine replacement therapies for smoking should be studied further for changes in movement.
참고문헌 (36)
- Meyer JM, "Future directions in tardive dyskinesia research", J Neurol Sci, 389, pp.76~80 (2018)
- Caroff SN, "Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia", J Clin Psychiatry, 72, pp.295~303 (2011)
- Stanley N. Caroff, "Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors", Clinical Psychopharmacology and Neuroscience, 18(2), pp.322~326 (2020), 대한정신약물학회[DOI]
- Ward KM, "Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management", Neurol Ther, 7, pp.233~248 (2018)
- Jeste DV, "Tardive dyskinesia and neuroleptics: from dogma to reason", pp.15~32 (1986), American Psychiatric Press
- Margolese HC, "Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction", Can J Psychiatry, 50, pp.541~547 (2005)
- Mahmoudi S, "Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model", Mov Disord, 29, pp.1125~1133 (2014)
- Conti MM, "A new outlook on cholinergic interneurons in Parkinson’s disease and L-DOPA-induced dyskinesia", Neurosci Biobehav Rev, 92, pp.67~82 (2018)
- Miller R, "Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia", Biol Psychiatry, 34, pp.713~738 (1993)
- Caroff SN, "Pharmacological treatment of tardive dyskinesia : recent developments", Expert Rev Neurother, 17, pp.871~881 (2017)
- Caroff SN, "Treatment of tardive dyskinesia with donepezil : a pilot study", J Clin Psychiatry, 62, pp.772~775 (2001)
- Tammenmaa-Aho I, "Cholinergic medication for antipsychotic-induced tardive dyskinesia", Cochrane Database Syst Rev, (3), pp.CD000207~ (2018)
- Caroff SN, "Treatment of tardive dyskinesia with galantamine : a randomized controlled crossover trial", J Clin Psychiatry, 68, pp.410~415 (2007)
- Bonsi P, "Centrality of striatal cholinergic transmission in Basal Ganglia function", Front Neuroanat, 5, pp.6~ (2011)
- Bordia T, "Varenicline is a potent partial agonist at 62* nicotinic acetylcholine receptors in rat and monkey striatum", J Pharmacol Exp Ther, 342, pp.327~334 (2012)
- Quik M, "Potential therapeutic application for nicotinic receptor drugs in movement disorders", Nicotine Tob Res, 21, pp.357~369 (2019)
- Quik M, "Nicotine and nicotinic receptor drugs : potential for Parkinson’s disease and drug-induced movement disorders", Int Rev Neurobiol, 124, pp.247~271 (2015)
- Bordia T, "Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats", J Pharmacol Exp Ther, 340, pp.612~619 (2012)
- Evins AE, "Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with psychotic, anxiety, and mood disorders in the EAGLES trial", J Clin Psychopharmacol, 39, pp.108~116 (2019)
- Shim JC, "Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia : a randomized double-blind placebo-controlled trial", Neuropsychopharmacology, 37, pp.660~668 (2012)
- Smith RC, "Varenicline effects on smoking, cognition, and psychiatric symptoms in schizophrenia : a double-blind randomized trial", PLoS One, 11, pp.e0143490~ (2016)
- Williams JM, "A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder", J Clin Psychiatry, 73, pp.654~660 (2012)
- Uca AU, "Parkinsonism related to varenicline in a patient during smoking cessation", J Clin Psychopharmacol, 35, pp.355~357 (2015)
- Toffey BA, "Withdrawal-emergent dyskinesias following varenicline therapy", Open Neurol J, 9, pp.7~8 (2015)
- Goff DC, "Cigarette smoking in schizophrenia : relationship to psychopathology and medication side effects", Am J Psychiatry, 149, pp.1189~1194 (1992)
- George TP, "Medical illness and schizophrenia", pp.81~98 (2003), American Psychiatric Publishing, Inc
- Jin Y, "Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE : impact of race and smoking", J Clin Pharmacol, 50, pp.73~80 (2010)
- Diehl A, "Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial", Eur Psychiatry, 24, pp.33~40 (2009)
- Glazer WM, "Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications", J Clin Psychiatry, 54, pp.133~139 (1993)
- Guy W, "ECDEU assessment manual for psychopharmacology", pp.534~537 (1976), Alcohol Drug Abuse and Mental Health Administration
- Brown RA, "Reliability and validity of a smoking timeline follow-back interview", Psychol Addict Behav, 12, pp.101~112 (1998)
- Simpson GM, "A rating scale for extrapyramidal side effects", Acta Psychiatr Scand Suppl, 212, pp.11~19 (1970)
- Barnes TR, "A rating scale for drug-induced akathisia", Br J Psychiatry, 154, pp.672~676 (1989)
- de Leon J, "The pharmacokinetics of paliperidone versus risperidone", Psychosomatics, 51, pp.80~88 (2010)
- Schoretsanitis G, "Effect of smoking on risperidone pharmacokinetics-a multifactorial approach to better predict the influence on drug metabolism", Schizophr Res, 185, pp.51~57 (2017)
- Taha Can Tuman, "Tardive Dyskinesia Associated with Bupropion", Clinical Psychopharmacology and Neuroscience, 15(2), pp.194~196 (2017), 대한정신약물학회[DOI]